Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Comment by ready2go1on Aug 09, 2011 6:38pm
295 Views
Post# 18923897

RE: FDA meeting confirm by FDA

RE: FDA meeting confirm by FDAI noticed that the news came out on the FDA site on Sunday night. Surprised that neither GPRO or CUR has released this but maybe they are not permitted. (for the most part, no one is aware that this is taking place, except the hand full that read this board.) I have been buying over the past several months but I did not pull the trigger since the drop in price. At some point this meeting date will be reflected in the share price and with a positive vote of approval from the panel we should be on our way to $3.00. There continues to be a # of studies published on an ongoing basis and many of them make there way on to the board. With all the cost cutting coming, this is, Prime Time for pca3 to hit the market.
     The race in my mind now becomes CUR getting listed her in the U.S. before they get acquired. We will get to $4.00 at some point in the near term but much higher the following year if we we can remain a stand alone company. Today here in the States Diagnocure has a share price between $1.50 to $2.00. 
     Market has been difficult and even before, the stock reacted to very small market sell orders that have set the tone, I am looking to see someone step up and get momentum back on our side and get us off to the races. Those ask orders will be pulled in a blink of an eye.
Bullboard Posts